Laboratory of Metabolism, Inflammation and Diseases
Drug Discovery Center at the School of Chemical Biology & Biotechnology

Reading Materials


42. Daugherty A, Tall AR, Daemen MJAP,et al. Recommendation on Design, Execution, and Reporting of Animal Atherosclerosis Studies: A Scientific Statement From the American Heart Association.Arterioscler Thromb Vasc Biol. 2017 Sep;37(9):e131-e157.28729366.pdf

41. Daugherty A, Tall AR, Daemen MJAP, et al. Recommendation on Design, Execution, and Reporting of Animal Atherosclerosis Studies: A Scientific Statement From the American Heart Association. Circ Res. 2017 Sep 1;121(6):e53-e79.28729353.pdf

40. Robinet P, Milewicz DM, Cassis LA, et al. Consideration of Sex Differences in Design and Reporting of Experimental Arterial Pathology Studies-Statement From ATVB Council. Arterioscler Thromb Vasc Biol. 2018 Feb;38(2):292-303. 29301789.pdf

39. Brooks GA. The Science and Translation of Lactate Shuttle Theory. Cell Metab. 2018 Apr 3;27(4):757-85. 29617642.pdf

38. Di Carlo SE, Peduto L. The perivascular origin of pathological fibroblasts. J Clin Invest. 2018 Jan 2;128(1):54-63. 29293094.pdf

37. Childs BG, Li H, van Deursen JM. Senescent cells: a therapeutic target for cardiovascular disease. J Clin Invest. 2018 Apr 2;128(4):1217-1228.29608141.pdf

36. Palazon A, Goldrath AW, Nizet V, et al. HIF transcription factors, inflammation, and immunity.Immunity. 2014 Oct 16;41(4):518-28.25367569.pdf

35. Zhao H, Dennery PA, Yao H. Metabolic reprogramming in the pathogenesis of chronic lung diseases, including BPD, COPD, and pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2018 Apr 1;314(4):L544-L554.29351437.pdf

34. Feng B, Cao Y, Chen S, et al. miR-200b Mediates Endothelial-to-Mesenchymal Transition in Diabetic Cardiomyopathy. Diabetes. 2016 Mar;65(3):768-79.26718496.pdf

33. Sterk, P J, and K F Rabe. “The Joy of Writing a Paper Why Am I Doing This ? What Do I Need to Consider in Advance ?” Breathe 4 (2008): 225–232. Breathe. Web.pdf

32. Dasgupta S, Rajapakshe K, Zhu B, et al. Metabolic enzyme PFKFB4 activates transcriptional coactivator SRC-3 to drive breast cancer. Nature. 2018 Apr;556(7700):249-254.29615789.pdf

31. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008 Jan;214(2):199-210.18161745.pdf

30. Bierhansl L, Conradi LC, Treps L, et al. Central Role of Metabolism in Endothelial Cell Function and Vascular Disease.Physiology (Bethesda). 2017 Mar;32(2):126-140.28202623.pdf

29. Galkina E, Kadl A, Sanders J, et al. Lymphocyte recruitment into the aortic wall before and during development of atherosclerosis is partially L-selectin dependent. J Exp Med. 2006 May 15;203(5):1273-82.16682495.pdf

28. Lee YS, Wollam J, Olefsky JM.An Integrated View of Immunometabolism.Cell. 2018 Jan 11;172(1-2):22-40.29328913.pdf

27. Daugherty A, Tall AR, Daemen MJAP, et al. Recommendation on Design, Execution, and Reporting of Animal Atherosclerosis Studies: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2017 Sep;37(9):e131-e157. 28729366.pdf

26. Weber C, von Hundelshausen P. CANTOS Trial Validates the Inflammatory Pathogenesis of Atherosclerosis: Setting the Stage for a New Chapter in Therapeutic Targeting. Circ Res. 2017 Oct 27;121(10):1119-1121.29074528.pdf

25. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017 Sep 21;377(12):1119-1131.28845751.pdf

24. Ridker PM, MacFadyen JG, Thuren T, et al. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet. 2017 Oct 21;390(10105):1833-1842.28855077.pdf

23. Xi H, Zhang Y, Xu Y, et al. Caspase-1 Inflammasome Activation Mediates Homocysteine-Induced Pyrop-Apoptosis in Endothelial Cells. Circ Res. 2016 May 13;118(10):1525-39.27006445.pdf

22. Guo H, Callaway JB, Ting JP. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat Med. 2015 Jul;21(7):677-87.26121197.pdf

21. Siroon Bekkering,Jessica Quintin, et al. Oxidized Low-Density Lipoprotein Induces Long-term Proinflammatory Cytokine Production and Foam Cell Formation via Epigenetic Reprogramming of Monocytes. Arterioscler Thromb Vasc Biol. 2014 Aug; 34: 1731-1738.24903093.pdf

20. Schoors S, De Bock K, Cantelmo AR, et al. Partial and transient reduction of glycolysis by PFKFB3 blockade reduces pathological angiogenesis. Cell Metab. 2014 Jan 7;19(1):37-48.  24332967.pdf

19.  Morote-Garcia JC, Rosenberger P, Kuhlicke J, Eltzschig HK. HIF-1-dependent repression of adenosine kinase attenuates hypoxia-induced vascular leak. Blood. 2008 Jun 15;111(12):5571-80.  18309031.pdf

18. Byles V, Covarrubias AJ, Ben-Sahra I, Lamming DW, Sabatini DM, Manning BD, Horng T. The TSC-mTOR pathway regulates macrophage polarization. Nat Commun. 2013;4:2834.  24280772.pdf

17. Lan F1, Cacicedo JM, Ruderman N, Ido Y. SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1. Possible role in AMP-activated protein kinase activation. J Biol Chem. 2008 Oct 10;283(41):27628-35.  18687677.pdf

16. Fu X, Zhao JX, Zhu MJ, Foretz M, Viollet B, Dodson MV, Du M. AMP-activated protein kinase α1 but not α2 catalytic subunit potentiates myogenin expression and myogenesis. Mol Cell Biol. 2013 Nov;33(22):4517-25.  24043309.pdf

15. Bando H1, Atsumi T, Nishio T, Niwa H, Mishima S, Shimizu C, Yoshioka N, Bucala R, Koike T. Phosphorylation of the 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase/PFKFB3 family of glycolytic regulators in human cancer. Clin Cancer Res. 2005 Aug 15;11(16):5784-92.  16115917.pdf

14. Yang XD, Huang B, Li M, Lamb A, Kelleher NL, Chen LF. Negative regulation of NF-kappaB action by Set9-mediated lysine methylation of the RelA subunit. EMBO J. 2009 Apr 22;28(8):1055-66.  19262565.pdf

13.  Zhang Y, Choksi S, Chen K, Pobezinskaya Y, Linnoila I, Liu ZG. ROS play a critical role in the differentiation of alternatively activated macrophages and the occurrence of tumor-associated macrophages. Cell Res. 2013 Jul;23(7):898-914.  23752925.pdf

12. Romeo GR, Lee J, Shoelson SE. Metabolic Syndrome, Insulin Resistance, and Roles of Inflammation-Mechnisms and Therapeutic Targets. Arterioscler Thromb Vasc Biol. 2012 Aug;32(8):1771-6.  22815343.pdf

11. Hoeksema MA, Stöger JL, de Winther MP. Molecular Pathways Regulating Macrophage Polarization: Implications for Atherosclerosis. Curr Atheroscler Rep. 2012 Jun;14(3):254-63. 22407286.pdf

10. Bornfeldt KE, Tabas I. Insulin Resistance, Hyperglycemia and Atherosclerosis. Cell Metabolism2011 Nov 2;14(5):575-85. 22055501.pdf 

9. Chow A, Brown BD, Merad M. Studying the mononuclear phagocyte system in the molecular age. Nat Rev Immunol. 2011 Oct 25;11(11):788-98.22025056.pdf

8. Saijo K, Glass CK. Microglial cell origin and phenotypes in health and disease. Nat Rev Immunol. 2011 Oct 25;11(11):775-87.22025055.pdf

7. Lawrence T, Natoli G. Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat Rev Immunol. 2011 Oct 25;11(11):750-61.22025054.pdf

6. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol. 2011 Oct 14;11(11):723-37.21997792.pdf 

5. Shi C, Pamer EG. Monocyte recruitment during infection and inflammation. Nat Rev Immunol. 2011 Oct 10;11(11):762-74.21984070.pdf

4. Chawla A, Nguyen KD, Goh YP. Macrophage-mediated inflammation in metabolic disease. Nat Rev Immunol. 2011 Oct 10;11(11):738-49.21984069.pdf

3. Klaus Ley, Yury I. Miller, Catherine C. Hedrick  Monocyte and Macrophage Dynamics During Atherogenesis. Arterioscler Thromb Vasc Biol. 2011;31:1506-1516. 21677293.pdf 

2. Tabas I, Seimon T, Timmins J, Li G, Lim W. Macrophage Apoptosis in Advanced AtherosclerosisIntergrative Physiology: Ann. N.Y. Acd. Sci. 2009 Sep;1173 Suppl 1:E40-5.19751413.pdf

1. Tedgui A, Mallat Z. Cytokines in Atherosclerosis: Pathogenic and Regulatory Pathways. Physiol Rev. 2006 Apr;8  (2):515-81.  16601268.pdf